BIODESIX INC Income Statement
BDSX|6 years of annual SEC 10-K data (FY2020-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
BIODESIX INC reported $88M in revenue and $35M in net loss for FY2025. Revenue has grown at a 29.2% compound annual rate over the past 5 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -4.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $88.5M | $71.3M | $49.1M | $38.2M | $45.6M | $24.6M |
| SG&A Expense | $87.5M | $80.5M | $67.4M | $61.5M | $34.9M | $30.6M |
| R&D Expense | $12.0M | $9.6M | $10.0M | $13.1M | $10.8M | $10.5M |
| Operating Income | -$27.9M | -$34.5M | -$41.3M | -$50.6M | -$22.9M | -$26.7M |
| Interest Expense | $7.7M | $8.3M | $9.5M | $8.1M | $7.6M | $3.0M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$35.3M | -$42.9M | -$52.1M | -$65.4M | -$31.4M | -$30.7M |
| EPS (Basic) | -$6.64 | -$0.64 | -$1.55 | -$1.58 | - | - |
| EPS (Diluted) | -$6.64 | -$0.64 | -$1.55 | -$1.58 | -$6.48 | -$126.97 |
| Shares Outstanding | 7.3M | 96.2M | 77.6M | 30.8M | 26.6M | 254.9K |
| Operating Margin | -31.5% | -48.4% | -84.2% | -132.4% | -50.3% | -108.9% |
| Profit Margin | -39.9% | -60.2% | -106.2% | -171.3% | -68.8% | -125.2% |